Literature DB >> 23607751

Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

P Cipriani1, P Di Benedetto, V Liakouli, B Del Papa, M Di Padova, M Di Ianni, A Marrelli, E Alesse, R Giacomelli.   

Abstract

Systemic sclerosis (SSc) is a chronic disease, with early activation of the immune system. The aim of our work was to address how SSc-mesenchymal stem cells (MSCs), although senescent, might preserve specific immunomodulatory abilities during SSc. MSCs were obtained from 10 SSc patients and 10 healthy controls (HC). Senescence was evaluated by assessing cell cycle, β-galactosidase (β-Gal) activity, p21 and p53 expression; doxorubicin was used as acute senescence stimulus to evaluate their ability to react in stressed conditions. Immunomodulatory abilities were studied co-culturing MSCs with peripheral blood mononuclear cells (PBMCs) and CD4(+) cells, in order to establish both their ability to block proliferation in mixed lymphocyte reaction and in regulatory T cells (Tregs) induction. SSc-MSC showed an increase of senescence biomarkers. Eighty per cent of MSCs were in G0-G1 phase, without significant differences between SSc and HC. SSc-MSCs showed an increased positive β-Gal staining and higher p21 transcript level compared to HC cells. After doxorubicin, β-Gal staining increased significantly in SSc-MSCs. On the contrary, doxorubicin abolished p21 activation and elicited p53 induction both in SSc- and HC-MSCs. Interleukin (IL)-6 and transforming growth factor (TGF)-β-related transcripts and their protein levels were significantly higher in SSc-MSCs. The latter maintained their immunosuppressive effect on lymphocyte proliferation and induced a functionally regulatory phenotype on T cells, increasing surface expression of CD69 and restoring the regulatory function which is impaired in SSc. Increased activation of the IL-6 pathway observed in our cells might represent an adaptive mechanism to senescence, but preserving some specific cellular functions, including immunosuppression.
© 2013 British Society for Immunology.

Entities:  

Keywords:  immunomodulatory abilities; mesenchymal stem cells; senescence; systemic sclerosis

Mesh:

Substances:

Year:  2013        PMID: 23607751      PMCID: PMC3722920          DOI: 10.1111/cei.12111

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  60 in total

1.  Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.

Authors:  Song Guo Zheng; J Dixon Gray; Kazuo Ohtsuka; Satoshi Yamagiwa; David A Horwitz
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

Review 2.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

3.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

4.  Elevated serum level of interleukin-10 in patients with systemic sclerosis.

Authors:  E J Kucharz; L Brzezinska-Wcislo; A Kotulska; W Gasiorowska-Kielkowska; J Gozdzik
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

5.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

Authors:  Massimo Di Nicola; Carmelo Carlo-Stella; Michele Magni; Marco Milanesi; Paolo D Longoni; Paola Matteucci; Salvatore Grisanti; Alessandro M Gianni
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

6.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.

Authors:  William T Tse; John D Pendleton; Wendy M Beyer; Matthew C Egalka; Eva C Guinan
Journal:  Transplantation       Date:  2003-02-15       Impact factor: 4.939

7.  Expression of transforming growth factor type beta on human epidermal dendritic cells.

Authors:  M S Gruschwitz; O P Hornstein
Journal:  J Invest Dermatol       Date:  1992-07       Impact factor: 8.551

Review 8.  Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

Authors:  Todd M Brusko; Amy L Putnam; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

Authors:  Joachim Oswald; Sabine Boxberger; Birgitte Jørgensen; Silvia Feldmann; Gerhard Ehninger; Martin Bornhäuser; Carsten Werner
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

10.  TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors.

Authors:  Shuang Fu; Nan Zhang; Adam C Yopp; Dongmei Chen; Minwei Mao; Dan Chen; Haojiang Zhang; Yaozhong Ding; Jonathan S Bromberg
Journal:  Am J Transplant       Date:  2004-10       Impact factor: 8.086

View more
  29 in total

1.  Co-transplantation of syngeneic mesenchymal stem cells improves survival of allogeneic glial-restricted precursors in mouse brain.

Authors:  Amit K Srivastava; Camille A Bulte; Irina Shats; Piotr Walczak; Jeff W M Bulte
Journal:  Exp Neurol       Date:  2015-10-26       Impact factor: 5.330

Review 2.  The Challenge in Using Mesenchymal Stromal Cells for Recellularization of Decellularized Cartilage.

Authors:  Zhao Huang; Owen Godkin; Gundula Schulze-Tanzil
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

3.  Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Konstantinos Porpodis; Ioannis Kioumis; Sofia Lampaki; Lonny Yarmus; Raf Malecki; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Cancer Res Ther (Manch)       Date:  2014

4.  Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis.

Authors:  Chiara Capelli; Eleonora Zaccara; Paola Cipriani; Paola Di Benedetto; Wanda Maglione; Romina Andracco; Gabriele Di Luca; Francesca Pignataro; Roberto Giacomelli; Martino Introna; Claudio Vitali; Nicoletta Del Papa
Journal:  Cell Transplant       Date:  2017-01-31       Impact factor: 4.064

Review 5.  Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis.

Authors:  Xiufen Zhuang; Xiao Hu; Shuren Zhang; Xingmin Li; Xiaoying Yuan; Yanhong Wu
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-15       Impact factor: 8.667

6.  Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1.

Authors:  Rebecca Lee; Nicoletta Del Papa; Martin Introna; Charles F Reese; Marina Zemskova; Michael Bonner; Gustavo Carmen-Lopez; Kristi Helke; Stanley Hoffman; Elena Tourkina
Journal:  J Scleroderma Relat Disord       Date:  2019-01-25

Review 7.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 8.  Endothelial-to-mesenchymal transition in systemic sclerosis.

Authors:  P Cipriani; R Giacomelli; P Di Benedetto; P Ruscitti; O Berardicurti; M Vomero; L Navarini; V Dolo
Journal:  Clin Exp Immunol       Date:  2021-04-18       Impact factor: 5.732

9.  Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial.

Authors:  Brigitte Granel; Aurélie Daumas; Elisabeth Jouve; Jean-Robert Harlé; Pierre-Sébastien Nguyen; Christian Chabannon; Nathalie Colavolpe; Jean-Charles Reynier; Romain Truillet; Stéphanie Mallet; Antoine Baiada; Dominique Casanova; Laurent Giraudo; Laurent Arnaud; Julie Veran; Florence Sabatier; Guy Magalon
Journal:  Ann Rheum Dis       Date:  2014-08-11       Impact factor: 19.103

Review 10.  From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases.

Authors:  Raghavan Chinnadurai; Edmund K Waller; Jacques Galipeau; Ajay K Nooka
Journal:  Biomed Res Int       Date:  2013-11-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.